  Objective: To discover candidate drugs to repurpose for COVID-19 using
literature-derived knowledge and knowledge graph completion methods. Methods:
We propose a novel, integrative, and neural network-based literature-based
discovery (LBD) approach to identify drug candidates from both PubMed and
COVID-19-focused research literature. Our approach relies on semantic triples
extracted using SemRep (via SemMedDB). We identified an informative subset of
semantic triples using filtering rules and an accuracy classifier developed on
a BERT variant, and used this subset to construct a knowledge graph. Five SOTA,
neural knowledge graph completion algorithms were used to predict drug
repurposing candidates. The models were trained and assessed using a time
slicing approach and the predicted drugs were compared with a list of drugs
reported in the literature and evaluated in clinical trials. These models were
complemented by a discovery pattern-based approach. Results: Accuracy
classifier based on PubMedBERT achieved the best performance (F1= 0.854) in
classifying semantic predications. Among five knowledge graph completion
models, TransE outperformed others (MR = 0.923, Hits@1=0.417). Some known drugs
linked to COVID-19 in the literature were identified, as well as some candidate
drugs that have not yet been studied. Discovery patterns enabled generation of
plausible hypotheses regarding the relationships between the candidate drugs
and COVID-19. Among them, five highly ranked and novel drugs (paclitaxel, SB
203580, alpha 2-antiplasmin, pyrrolidine dithiocarbamate, and butylated
hydroxytoluene) with their mechanistic explanations were further discussed.
Conclusion: We show that an LBD approach can be feasible for discovering drug
candidates for COVID-19, and for generating mechanistic explanations. Our
approach can be generalized to other diseases as well as to other clinical
questions.
